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Gold coated magnetite nanoparticles were prepared and coated with ranibizumab as an ocular drug 
delivery system. The surface morphologies of the nanoparticles were determined by Scanning 
Electron Microscopy (SEM). The size and surface charge were determined by using the dynamic 












Conjugation of ranibizumab onto nanoparticles was achieved using 
the physical adsorption method. The amount of ranibizumab on the surface of the nanoparticles was 
determined by thermogravimetric analysis (TGA). In the in vitro release studies performed using UV 
spectroscopy; it was found that almost 60% of antibodies were released within the first 30 minutes. 





particles were proved with MTT. Results of the studies, showed that the antibody conjugated 
magnetic nanoparticle system could be a potential treatment system for ocular diseases.
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INTRODUCTION
Age-related Macular Degeneration (AMD) is the 
major cause of irreversible vission loss in the world 
in people 50 years of age or elderly population in the 
world (Eter et al., 2006). AMD can be present in two 
forms, atrophic (also known as non-neovascular AMD, 
geographic atrophy or dry AMD) or choroidal neovascular 
AMD (CNV) (also called exudative or wet AMD) (Van 
Leeuwen et al., 2003). In the 1980s laser photocoagulation 
was used for the treatment of neovascular AMD. 
Treatment with laser was effective in reducing long-term 
severe visual loss, however it was limited by lack of vision 
gain and high recurrence rates (50%) (Lim et al., 2012). 
Photodynamic therapy (PDT) with verteporfin has been 
used in the 1990s for AMD treatment. In the treatment 
of AMD, verteporfin is used as the photosensitizer and 
is administered intravenously. After accumulation of 
verteporfin in neovascular membranes, the dye is activated 
with infrared light. This process generates oxygen-free 
radicals that damage the endothelium, promoting closure 
of newly formed vessels (Lim et al., 2012; Schmidt-Erfurth, 
Hasan, 2000). Intravitreal antiangiogenic therapies are 
currently the primary therapy for neovascular age-related 
macular degeneration. Intravitreal injections limit therapy 
to the eye, avoiding systemic administration and possibly 
reducing the incidence of systemic adverse effects (Jager 
et al., 2008). 
New vessel growth is a complex process requiring 
activation of several receptors and growth factors. Of 
these growth factors, the vascular endothelial growth 
factor (VEGF) is essential for proper physiological 
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angiogenesis. Therefore, the target of the treatments 
is the inhibition of VEGF (Penn et al., 2008). Sodium 
Pegaptanib (Macugen, Eyetech Pharmaceuticals, Inc., 
New York, NY) was approved by the US Food and 
Drug Administration (FDA) in December 2004 for 
the treatment of neovascular AMD (Eter et al., 2006, 
Kourlas and Schiller, 2006). VEGF Trap (Aflibercept, 
Regeneron, Tarrytown, New York, USA) is a fusion 
protein that bind to VEGF, has recently received FDA 
approval for the treatment of neovascular age-related 
macular degeneration treatment (Lim et al., 2012). Over 
the past two decades, the most common treatment used 
for neovascular AMD is based on monoclonal antibody 
dependent inhibition of VEGF. By so doing regression of 
revascularization and improved vision is provided (Volz, 
Pauly, 2015). Bevacizumab (Avastin, Genentech, Inc., 
South San Francisco, CA) is a humanized monoclonal 
antibody that binds to VEGF, which was designed for 
IV administration and is approved for the treatment 
of colorectal cancer (Avery et al., 2006). It is also 
increasingly being used off-label as intravitreal therapy 
for neovascular age-related macular degeneration since 
2005 (Jager et al., 2008). 
Ranibizumab (Lucentis®, Genentech, Inc., San 
Francisco, CA, USA) is a humanized antigen-binding 
fragment (Fab) that neutralizes all VEGF-A isoforms. 
Ranibizumab was derived from the murine monoclonal 
antibody A4.6.1., such as bevacizumab (Spitzer et al., 
2008). However, bevacizumab was derived from Fab-
Fab-12 while ranibizumab was derived from a different 
humanized anti-VEGF Fab variant known as MB1.6. 
through a series of phage display steps. Affinity selection 
using phage display technology increased the affinity of 
Ranibizumab for VEGF-A by several times (Spitzer et al., 
2008; Chen et al., 1999; Baca et al., 1997). Because of the 
improved affinity improvement, ranibizumab was 5- to 
20- fold more potent than bevacizumab in spite of the fact 
that it had only one antigen binding site. Also the Lack 
of the Fc (Fragment crystallizable) region  prevents the 
promotion of intraocular inflammation after intravitreal 
injection (Spitzer et al., 2008, Ferrara et al., 2006). In 
June 2006, ranibizumab was approved by FDA for the 
treatment of neovascular AMD (Ferrara et al., 2006).
Local delivery of antibodies can provide  substantial 
benefits such as; higher local bioavailability, reduced 
systemic drug exposure, lower dose of antibody and 
consequently reduced side effects. However, there are 
some factors that limit local antibody applications, such 
as increased dose frequency due to the short life span 
of antibodies, invasiveness of the administration to 
some sites and accordingly reactions at the injection site 
(Schweizer et al., 2014; Orive et al., 2003). For example, 
intravitreal injections are used for AMD treatment. 
However, the treatment efficacy is limited by repeated 
applications, systemic exposure, and poor availability 
in the posterior segments of the eye. Intravitreal 
applications also have disadvantages such as patient 
discomfort, eye infections, high intraocular pressure, 
retinal vascular occlusion or retinal detachment (Witting 
et al., 2015). Drug delivery systems can provide more 
effective treatment by removing these limitations. 
Nanoparticles are very small particles that vary 
in size from 10 nm to 1000 nm and which consist of 
macromolecular substances (Singh, Lillard, 2009). 
There are many types of nanoparticles with differing 
sizes, shapes, composition and functionality. Some 
of these are liposomes, albumin bound nanoparticles, 
polymeric nanoparticles, magnetic nanoparticles and 
quantum dot (Wang, Wang, 2014). Nanoparticles 
have been used in many areas such as engineering, 
electronics and computers, cosmetic, environmental, 
food, transportation and biomedicine. Some examples 
of nanoparticle applications in biomedicine include 
detecting analytes, pathogens, cells or molecular 
functions as a biosensor, novel labels and contrast 
agents in molecular imaging, targeted drug delivery, 
diagnosis of diseases, gene delivery and biocompatible 
coatings for implants (Wang, Wang, 2014; Nagarajan, 
Hatton, 2008).
Magnetic nanoparticles show a response to an 
applied magnetic field. Manipulation by the applied 
external magnetic field makes them attractive 
in targeting studies (Issa et al., 2013). Magnetic 
nanoparticles have widespread application in 
biotechnology, biomedical, material science, engineering 




) and its 




) are the most 
commonly used magnetic nanoparticles because of 
theirtheir non-toxic and biocompatibility properties 
(Akbarzadeh et al., 2012). In order to control the toxicity 
properties of magnetic nanoparticles, the surface can 
be coated with different materials such as polymer, 
silica, carbon or gold (Bucak et al., 2012). Biomedical 
application can be classified into two categories, two 
categories: in vitro and in vivo. For in vitro applications, 
the main use is for diagnostics applications such as 
separating and selection, magnetic resonance imaging 
and bioseperation of biomolecules, such as protein, cell, 
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DNA/RNA, microorganism. In vivo applications are 
therapeutic applications such as hyperthermia, drug 
delivery and diagnostic applications such as NMR 
imaging (Issa et al., 2013; Frimpong, Hilt, 2010).
Gold is an inert element and very useful as a coating 
material for protecting magnetic nanoparticles, its unique 
biocompatibility, versatility in surface modification 
and high catalytic properties. For these reasons gold 
coating of magnetic nanoparticles has attracted much 
attention over the past several years as they can be used 
in biotechnological and biomedical areas, including drug 
delivery (Ahmed et al., 2014; Xing et al., 2015).
Physical adsorption method uses non-covalent 
modes of binding based on a combination of electrostatic 
and hydrophobic interactions of the antibody and the gold 
surface. The antibodies or other functionalized groups are 
nonspecifically adsorbed onto gold nanoparticles while still 
keeping the nanoparticles negatively charged, providing 
stability in colloidal solution. Non-covalent technique 
is described as spontaneous absorption of antibodies 
onto the surface of citrate stabilized nanoparticles; 
there are several types of interactions which may occur 
in this process including hydrophobic interactions and 
ionic interactions. Hydrophobic interactions are due to 
attraction between hydrophobic parts of the antibody and 
the metal surface which results in the formation of a non-
covalent bond. Positively charged groups are abundant 
in antibodies i.e., positively charged amino acids and the 
N-terminal are present. Ionic interactions are formed 
between these groups and the negatively charged surface 
of the particles (Jazayeri et al., 2016).
The toxicity of iron oxide nanoparticles and gold 
nanoparticles were evaluated and it was proved that these 
materials are non-toxic for ocular tissues (Raju et al., 2011; 
Söderstjerna et al., 2014; Hun Kim et al., 2009; Soenen 
et al., 2011). From this point of view, it is suggested that 
prepared gold coated nanoparticles in this study can be an 
alternative drug delivery system for ocular treatment.
In the present work, a drug delivery system that can 
be manipulated by applying an external magnetic field is 
developed for use in ocular treatments. For this purpose, 
ranibizumab antibody conjugated gold coated magnetic 
nanoparticles were prepared. Furthermore, in vitro 
characterization studies were performed on particles, 
including: drug loading and release profile, Scanning 
Electron Microscopy (SEM), Thermogravimetric 
Analysis (TGA), Dynamic Light Scattering (DLS), 
and X-Ray Diffraction (XRD). Antibody activity after 





 particles was evaluated with MTT test 
using HUVEC cell culture.
MATERIAL AND METHODS
Material
Gold (III) chloride trihydrate was purchased from 
Sigma-Aldrich Co. (USA). Ranibizumab was a generous 
gift from ATABAY Kimya San. ve Tic. A.S. (TURKEY) 











 magnetic nanoparticles were prepared by 
using co-precipitation method (Gupta et al., 2005). In 
this method nanoparticles were synthesized through co-
precipitation of Fe3+ and Fe2+ with sodium hydroxide. 
Initially 80 mL distilled water was de-aerated with 
nitrogen gas for ½ hours. The solution was heated up 
to 80 ºC in a reactor while stirring mechanically. After 
½ hour, 0.648 g of iron chloride (FeCl
3
) and 0.559 g of 




O) were dissolved 
in the reaction medium under nitrogen gas. After 15 
minutes, 20 mL of 1.5 M sodium hydroxide (NaOH) was 
added as a base. Upon this addition, blackening of the 
solution was observed immediately, which suggests the 
formation of magnetite nanoparticles. These chemicals 
were mixed for another ½ hour and then, the mixture 
was cooled down to room temperature. After synthesis, 
magnetite nanoparticles were collected by magnetic 
separation and the precipitate was washed twice with 




 nanoparticle solution 
was prepared in 50 mL of distilled water.









O was dissolved in 
120 mL of distilled water. This solution was then heated 
under reflux to boiling-point under  vigorous stirring 





dispersion was slowly added to HAuCl
4
 solution. After 
10 min, 5 mL of 80 mM sodium citrate solution was 
slowly added to the reaction mixture. This mixture was 
boiled under reflux with vigorous stirring for 5 min; the 
heating was then turned off, and the mixture was cooled 
to room temperature (Majouga et al., 2015). After 
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synthesis, nanoparticles were collected by magnetic 
separation and the precipitate was washed twice with 
distilled water. Red-brownish colored particles were 




 nanoparticle solution 





 concentration of gold coated nanoparticles 
was determined using “Tiron Metal Test” method 
(Bucak, Rende, 2013). Fe ions and tiron forms a colored 
complex which has a maximum absorbance value and 
intensity  at 480 nm spectrophotometrically (Lambda, 
Perkin Elmer, U.S.). This absorbance value is measured 
in order to obtain the concentration of magnetite by 
using below equation:
C (g/ml) =
(ABS at 480 nm) x (Dilution factor) x 231.52 x 25
39986 x 162.15 x 0.1
In this test, 0.1 mL nanoparticle solution was mixed 
with 0.4 mL of concentrated (37%) hydrochloric acid, this 
solution was then heated with a heat gun until the color 
of the solution changed to yellow. After color change, 
obtained solution was mixed with the 0.083 g/mL of 
tiron solution. 4 M, 3 mL of sodium hydroxide solution 
is added to the solution that turns red immediately. 
Finally, water was added until the final volume reaches 
25 mL. In order to measure the absorbance of the final 
solution, dilution was performed.
Preparation of Antibody Conjugated Nanoparticles
Antibodies were conjugated on nanoparticles 
using the “Physical Adsorption” method  (Singh et al., 
2009). In this method antibodies and nanoparticles were 
incubated together. 30, 45 and 60 µg of antibodies were 
diluted in 300 µL of 20 mM HEPES buffer (pH:6.8). 




 nanoparticle solution 
was taken and washed with distilled water by the help of 
a magnet. Then nanoparticles were diluted in 300 µL of 
20 mM HEPES buffer (pH:6.8). Antibody solution was 
added into prepared nanoparticle solution and mixed for 
2 hours with shaker at 100 rpm.
In vitro Release Studies and Conjugation Efficiency
After conjugation procedure, antibody conjugated 
nanoparticles were collected by the help of a magnet. 
Supernatant solutions were collected into different vials. 
In order to obtain conjugation efficiency, absorbance 
values of collected supernatant was measured between 
200 and 700 nm by using UV-Vis Spectroscopy. Instead 
of the taken buffer, 600 µL of PBS buffer (pH:7.4) was 
added as release medium onto collected nanoparticles. 
The shaking procedure was continued at 100 rpm for 48 
hours. At various time intervals, nanoparticles were held 
by magnet  from outside of the vial and 100 µL of samples 
were obtained. An equal volume  of fresh medium was 
added. In order to obtain release amount, collected samples 
were measured between 200 and 700 nm by using UV-Vis 
Spectroscopy (SPECTROstar, BMG Labtech, Germany). 
Nanoparticle Physicochemical Characterization





 particles were examined through Scanning 
Electron Microscopy (SEM; JEOL, JSM-5200, Japan). 
Before this analysis nanoparticles were dried overnight 
in a freeze-dryer (Scanvac, Coolsafe, Denmark). 
overnight. The dried nanoparticles were used for SEM 
images and surface morphology was determined.
Particle Size and Zeta Potential Determination





particles were measured by dynamic light scattering 
(DLS) using a NanoS Zeta Sizer (Malvern Zetasizer-
Nano ZS, U.K.). The measurements were performed at 
25 ºC with a laser diode illuminated light scatter sensor 
before and after antibody conjugation. After conjugation 
of different concentrations of antibodies, nanoparticles 
were collected with a magnet and the supernatant buffer 
was discharged. Then antibody conjugated nanoparticles 
were dissolved in distilled water as dispersion medium 
and measurements were performed. The average 
particle sizes with error ranges were obtained from three 
measurements of each sample.





were measured by electrophoretic mobility at 25 ºC 
using a NanoS Zeta Sizer (Malvern Zetasizer-Nano 
ZS, U.K.) which was used in the hydrodynamic size 
measurements. The measurements were performed 
before and after antibody conjugation. After conjugation 
of different concentration of antibodies, nanoparticles 
were collected with a magnet and supernatant buffer 
was discharged. Antibody conjugated nanoparticles 
were then dissolved  in distilled water as dispersion 
medium and measurements were performed. The 
surface charges with error ranges were obtained from 
three measurements of each sample.
Preparation and In Vitro Characterization of Monoclonal Antibody Ranibizumab Conjugated Magnetic Nanoparticles for Ocular Drug Delivery 
Braz. J. Pharm. Sci. 2020;56: e18171 Page 5/15
X-ray Diffraction (XRD)





 nanoparticles were recorded on an X-ray 
diffractometer (XRD; Bruker - D8 Advance, U.S.). 
Before the test, the samples were dried overnight in a 
freeze-dryer (Scanvac, Coolsafe, Denmark).
Thermogravimetric Analysis (TGA)
Thermogravimetric analysis (TGA; PerkinElmer - 
Pyris 1 TGA, U.S.) was used to indicate conjugation of 




 nanoparticle surface 
and to determine the amount of conjugated antibody. 
Before the test, the samples were dried overnight in a 
freeze-dryer (Scanvac, Coolsafe, Denmark). TGA of 




 nanoparticles with and without 
antibodies were performed at a heating speed of 10 ºC/
min under nitrogen where the temperature changed 
from 25 ºC to 600 ºC. The difference in weight loss was 
then determined.
Enzyme Linked Immunosorbent Assay (ELISA) Test
After in vitro drug release studies, sample 
concentrations were quantified using a commercially 
available ranibizumab ELISA kit (Alpha Diagnostic 
International, USA) in accordance with manufacturer’s 
instructions. OD readings were performed at 450 nm and 
antibody amounts in samples were calculated according 
to the standards used.
Cell Culture Experiments
Human umbilical vein endothelial cells 
(HUVECs, ATCC-CRL-1730) were cultured in M199 
medium (PAN Biotech, Germany) supplemented with 
20% FBS (PAN Biotech, Germany), 2% glutamine, 
1% penicillin/streptomycin (PAN Biotech, Germany) 
and maintained at 37 ºC in a humidified 5% CO
2
. 
Cultures were maintained with T75 flask and 96 
well plates were used for MTT tests. Nanoparticles 
used for cell culture studies were sterilized with 
UV for 30 minutes before experiments. Antibody 
and nanoparticle dilutions were performed in M199 
medium containing 2% FBS.





was determined using a commercially available MTT 
kit (Cayman, USA) in accordance with manufacturer’s 
instructions. The optical density was measured at 570 
nm. Nanoparticles which were previously calculated 
for magnetite concentration were diluted according to 
used antibody concentration. Evaluating of the effect of 
ranibizumab to HUVEC proliferation was also desired 
with antibody conjugated nanoparticles. Therefore first 
of all ranibizumab doses which can inhibit proliferation 
were  determined with MTT test in accordance with 
manufacturer’s instructions. 1 µg/100 µL, 2.5 µg/100 
µL, 5 µg/100 µL, 7.5 µg/100 µL and 10 µg/100 µL of 
ranibizumab doses were used to evaluating of anti-
angiogenic properties. 
RESULTS AND DISCUSSION
Characterization of Gold Coated Fe3O4 Nanoparticles
Magnetite nanoparticles prepared the co-
precipitation  method are black colored and, after the 
gold coating process, red-brown color. The change in 
color indicates that the particles were coated with gold 
Figure 1: A and C.
Pure gold nanoparticles may form during the 
coating process of magnetite nanoparticles. For this 
reason a separation step was performed with an external 





 (Wagstaff et al., 2012). Particles 
the solution moved towards the magnet outside of 
the vial. The supernatant solution had reddish color 
because the gold nanoparticles formed during coating 
procedure. The movement of the particles indicated 
that gold coated nanoparticles still preserved magnetic 





 nanoparticles combine Au characteristics and 
magnetite nanoparticles. Thus, these nanoparticles 
display optical properties for imaging and therapy. 
Nanoparticles can also be remotely delivered by 
an external magnetic field of targeted tissue in the 
body. It was shown that prepared nanoparticles have 
these properties as stated in the literature (Majouga 
et al.,2014). 
Prepared nanoparticles were entitled with codes. 




 nanoparticles was N 
before antibody conjugation. The code for 30 µg of 
antibody conjugated nanoparticles was N1, 45 µg of 
antibody conjugated nanoparticles was N2 and 60 µg of 
antibody conjugated nanoparticles was N3 TABLE I.
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particles after magnetic separation and separated gold nanoparticles.









 nanoparticles were characterized 
by the Dynamic Light Scattering (DLS) technique. DLS is 
used for obtaining the size distribution and zeta potential 
of nanoparticles with and without antibodies. As shown 





 particles have average size of approximately 162 
nm. After antibody conjugation, size of nanoparticles 
increased depending on the amount of antibody. Size of 
the antibody conjugated nanoparticles changed between 
232.9 nm and 472.8 nm. The increase in nanoparticle 





 nanoparticles were prepared 
with citrate so particles have negative surface charge 
(Majouga et al., 2014). As shown in TABLE I, zeta 
potential of the gold coated nanoparticles were found 
to be -21.1. After conjugation, conjugated antibodies 
shielded a sum of negative charge and the zeta potential 
of N1 was measured to be -13.9. However, because of 
the negative charge of antibodies, the surface charge 
was measured as negative. The zeta potential of N2 and 
N3 were measured as -14.8 and -16.8 respectively. It was 
shown that the amount of conjugated antibody did not 
considerably affect the zeta potential. DLS analyses 
showed that surface charge changed between -13.9 mV 
and -16.8 mV (TABLE I). 
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N - - 162.4±11.2 0.224±0.008 -21.1±0.23
After antibody 
conjugation 
N1 30 52.4±3.5 232.9±29 0.583±0.031 -13.9±1.77
N2 45 47.5±4.2 432.9±8.12 0.615±0.027 -14.8±0.50
N3 60 38.9±1.5 472.8±43.9 0.625±0.022 -16.8±0.10
X-ray Diffraction (XRD)





 nanoparticles were recorded on an X-ray 
diffractometer (XRD) Figure 4. 
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 nanoparticles the main characteristic 
peaks of Fe and Au are clearly visible. XRD pattern have diffraction peaks at 2θ= 38.2°, 44.4°, 65.6° and 77.5° which can be 
indexed to (111), (200), (220) and (311) planes of Au in the cubic phase (Robinson et al., 2010). Also have 30.3°, 35.5°, 43.2°, 
53.5°, 57°, 62.7° and 74.5° which correspond to the (220), (311), (400), (422), (511), (440) and (533) crystallographic planes of 
the inverse spinel magnetite crystal (Shrifian et al., 2015). XRD results confirm the formation of gold coating on the magnetite 
nanoparticles.
Antibody Conjugation and In vitro Release Studies 
The antibody conjugation process was performed 
in 20 mM HEPES buffer (pH:6.8) with shaker at 100 





nanoparticles is based on noncovalent binding of the 
antibodies at their isoelectric point (Sokolov et al., 2003; 
El-Sayed et al., 2006; El-Sayed et al., 2005). This point 
is very important in terms of stability of the conjugates. 
Although theoretical pI value of ranibizumab is ~8.8, 
it was demonstrated that ranibizumab has net negative 
charge at 7.4 pH (Li et al., 2011). As a result, 6.8 pH was 




 nanoparticles have a 
negative charge at 7.4 pH. 
In order to evaluate nanoparticle interference 
on antibody measurements, UV spectrometry 
measurements were performed with nanoparticles 
before antibody conjugation between 200 nm and 
700 nm. Obtained spectrum was used as baseline for 
antibody conjugated nanoparticles measurements. 
The calibration curve (R2 value of 0.995) was also 
obtained by recording the absorbance values of the 
antibodies with initial concentrations of 100 µg/mL, 
which were serially diluted to 5 µg/mL at 280 nm. The 
concentrations of unknown samples were estimated 
based on the antibody standard curve and nanoparticle 
baseline.
In the conjugation studies; it was found that 
although the amount of antibody increases, the efficiency 
of conjugation decreases as the antibody conjugated on 
the particle surface increased, TABLE I.  The antibody 
conjugation efficacy changed between 38.9% and 52.4% 
dependent on the amount of antibody.
Ranibizumab molecules have net negative charge at 
pH 7.4 and electrostatic repulsion between ranibizumab 




 particles will favor desorption. 
Hence, while conjugation studies were performed at 6.8 
pH, release studies were performed at 7.4 pH. In the in 
vitro release studies; it was found that although almost 
60% of antibody is released within the first 30 minutes, 
100% of antibody is released within 48 hours FIGURE 
5. Release data is shown in TABLE II.
Preliminary studies showed that the antibody 
remained stable for 48 hours. According to the 
information in the literature, it has been shown that the 
stability of Ranibizumab was maintained for a long time 
in the stability studies performed at different pH values 
(Veurink et al., 2011).
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 particles the main characteristic peaks of 
Fe and Au are clearly visible. XRD pattern has diffraction peaks at 2θ= 38.2 °, 44.4°, 65.6° and 77.5°, which can be indexed to 
(111), (200), (220) and (311) planes of Au in the cubic phase (Robinson et al., 2010). It also has 30.3°, 35.5°, 43.2°, 53.5°, 57°, 
62.7° and 74.5° which correspond to the (220), (311), (400), (422), (511), (440) and (533) crystallographic planes of the inverse 
spinel magnetite crystal (Shrifian et al., 2015). XRD results confirm the formation of gold coating on magnetite nanoparticles.














N1 64.5±5.4 71.1±4.1 70.6±8.3 83.3±6.2 98±1 100
N2 58.5±2.1 60.0±3.5 62.5±4.3 71.1±5.0 97.5±4.2 100
N3 59.3±5.6 64.7±8.5 68.0±8.5 81.6±12.3 92.8±9.7 100
Thermogravimetric Analysis (TGA)
The amount of ranibizumab on the surface of 
nanoparticles was determined by Thermogravimetric 
Analysis (TGA) in air atmosphere. The amount of 
ranibizumab on the surface of nanoparticles once and 
then dried in a vacuum oven at 60 ºC at 20 mbar. For TGA 
scan, temperature is increased from 25 ºC to 600 ºC. 
Thermogravimetric analysis is employed to determine 
the weight of antibodies with respect to total weight of 
the sample, indicating the amount of antibodies present 
on the nanoparticle surface (Mukherjee et al., 2007). 
While mass loss of organic molecules such as water, 
citrate or antibody occurred below 600 ºC, mass loss 
of inorganic molecules such as gold or iron oxide were 
found to be above  800 ºC (Villa et al.,2016; Van der Walt 
et al., 2010). In this study, only the mass loss of organic 
molecules was investigated therefor the temperature 
was increased to 600 ºC. This instrument measures the 
weight loss as a function of rising temperature as seen 
FIGURE 6.
As seen in FIGURE 6, A is mass loss of gold 







, while B is mass loss of antibody 











). In this 
equations, W
citrate
 is mass of citrate on nanoparticle 
surface, W
NP
 is the mass of nanoparticle, W
AB
 is the 
mass of conjugated antibody on the nanoparticle 
surface. Before antibody conjugation, analyzed sample 
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includes nanoparticles as inorganic molecules and 
citrate on nanoparticle surface as organic molecule. 
Due to the presence of citrate, a 14.6 % weight loss was 
calculated after analysis. After antibody conjugation 
the analyzed sample includes nanoparticles as 
inorganic molecules and citrate and antibodies on 
nanoparticle surface as organic molecules. Due to 
the presence of citrate and antibody, 30.18% weight 
loss was calculated after analysis. The difference 
between these two measurements reveals the amount 
of antibody that is associated with the nanoparticles. 
The difference of weight loss indicates the presence of 
antibody (Mukherjee et al., 2007). As a result, 15.58% 
of the antibody conjugated nanoparticle sample was 
antibody and it was shown that antibody conjugation on 
nanoparticles was achieved with physical adsorption 
method successfully.




 nanoparticles with and without antibody. A is mass loss of gold 






, B is mass loss of antibody conjugated gold coated 











Enzyme Linked Immunosorbent Assay (ELISA) Test
After in vitro drug release studies, sample 
concentrations were quantified using a commercially 
available Ranibizumab ELISA kit (Alpha Diagnostic 
International, USA) in accordance with manufacturer’s 
instructions. Biological functionality of the released 
antibodies also was evaluated. The results show that the 
antibody retains its biological activity after release from 
the nanoparticle. 
For ELISA test, only N2-code of antibody conjugated 
nanoparticles were used. The analysis demonstrated 
that, similar release profiles were obtained with UV 
Spectroscopy and ELISA. The results showed that, 
while approximately 50% conjugation efficiency was 
calculated with UV Spectroscopy, while approximately 
42.8% conjugation efficiency was calculated with 
ELISA test. The reason for this difference is that the 
ELISA test is a very sensitive method. The samples 
collected with the help of an external magnet may also 
contain nanoparticles in small quantities. As a result, 
the UV measurements may be affected. The conjugation 
efficiency calculated with UV Spectroscopy and ELISA 
were compared in TABLE III. 
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TABLE III - Comparing of conjugation efficiency calculated with UV Spectroscopy and ELISA for N2-code of antibody 
conjugated nanoparticles
Code
Conjugation efficiency calculated 
with UV Spectroscopy (%)













was determined using a commercially available MTT 
kit (Cayman, USA) in accordance with manufacturer’s 
instructions. Also, evaluating the effect of ranibizumab 
to HUVEC proliferation was desired for antibody 
conjugated nanoparticles. All ranibizumab doses that 
can inhibit proliferation were determined with MTT test 
in accordance with manufacturer’s instructions. 
The antibody concentrations that can be obtained 
by this system were chosen as max concentration. 
1 µg/100 µL, 2.5 µg/100 µL, 5 µg/100 µL, 7.5 µg/100 
µL and 10 µg/100 µL of Ranibizumab doses were used 
to evaluate anti-angiogenic properties. These doses 
were administered to HUVEC cell and after 24 hours 
MTT test was performed. As observed in FIGURE 
7, cell viability was not affected by ranibizumab at 
any concentration tested (Carneiro et al., 2009). The 
prepared concentrations were inadequate to prevent 
the proliferation of cells. It is necessary to use more 
nanoparticles to achieve higher concentrations with 
this drug system. This situation reduces the usability 
of the system, because low conjugation efficiency was 
obtained by the physical adsorption method. As a result, 




nanoparticles were not performed.
In the study of Lowe et al. in which the effect of 
ranibizumab on HUVEC proliferation was measured, 
it was shown that concentrations of 1.29 nM and 
FIGURE 7 - MTT test for evaluation of anti-angiogenic properties of ranibizumab with prepared concentration. 
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higher prevented proliferation (Lowe et al., 2007). In 
the study of Carneiro et al. it was demonstrated that 
ranibizumab concentrations of 0.06, 0.125 and 0.6 mg/
mL, which were tested in HUVEC cells did not show 
toxicity. In addition, it is shown that ranibizumab 
prevents proliferation at a concentration of 0.6 mg/
mL (Carneiro et al., 2009). Although, the doses used 
in our study were found to be insufficient to prevent 
proliferation, ranibizumab is an FDA approved 
drug for AMD and its effect on proliferation has 
been proven.
The cytotoxicity studies were performed with the 
amounts of nanoparticles which could be provided with 





 concentration calculated the Tiron test. 0.1 µg/
mL, 0.25 µg/mL, 0.5 µg/mL, 0.75 µg/mL and 1 µg/mL of 
concentrations were used for the MTT test. The results 
showed that the prepared nanoparticles are not toxic 
for HUVEC cells as indicated in the literature, Figure 
8 (Soenen et al., 2011; Raju et al., 2011). However, the 
magnetite concentration and cell viability could not be 
correlated. 
In the eye, the clearance mechanism of nanoparticles 
is unknown, but could involve uptake into the vascular 
system or passage through the hyaloid into the anterior 
chamber and egress out of the trabecular meshwork. After 
exiting the eye, the nanoparticles might be transported 
the lymphatic or systemic circulations and excreted 
in the liver and kidney. To evaluate ocular toxicity of 
magnetic nanoparticles, 50 nm and 4 µm dextran coated 
magnetic nanoparticles were injected by intravitreally 
to Sprague-Dawley rats. After 5 months iron deposition 
was only detected after 4 µm magnetic nanoparticles 
but not 50 nm magnetic nanoparticle injections. Of the 
50 nm magnetic nanoparticles which were cleared from 
the vitreous in these experiments, 4 µm particles were 
still detectable at 5 months. Intravitreal injections of 
magnetic nanoparticles also showed no signs of toxicity 
on retinal structure (Raju et al., 2011).
20 and 80 nm citrate stabilized gold nanoparticles 
are administered on ex vivo cultured post-natal mouse 
retina. Gold nanoparticles of both sizes were taken 
up by the retinal tissue and found to be distributed in 
all neuronal layers of the retina. Experimental studies 
show that gold nanoparticles after intravenous injection 
in mice pass cross the blood-retinal barrier and are 
detected in the CNS after systemic administration and 
induced no cytotoxicity in the retina (Söderstjerna et al., 
2014; Kim et al., 2009).
Using uncoated MNPs (not studied here) in 
vivo can be harmful, as it could lead to aggregation, 
increased oxidation, and/or other instability in 
physiologic conditions. Adapting the surface of the 
particles can enhance biological compatibility and allow 
functionalization of the surfaces to deliver drugs or to 
bind receptors on target sites. Iron oxide nanoparticles or 
or gold nanoparticles are safe to be used for biomedical 
purposes. For gold nanoparticles, the high persistence of 
the core itself does not require any special coatings in 
this regard (Raju et al., 2011; Soenen et al., 2011). 
The FDA has approved the use of superparamagnetic 
iron oxide nanoparticles as contrast agents in 
magnetic resonance imaging since 1996 (U.S. Food 
and Drug Administration), supporting the premise 
that nanoparticles prepared using iron oxide are not 
significantly harmful towards humans (Raju et al., 2011).





Magnetite concentration of nanoparticles (µg/mL)
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CONCLUSION





 nanoparticles could be synthesized and antibodies 
could can be conjugated on these nanoparticles. The 
nanoparticles were characterized by several techniques, 





 nanoparticles which antibody was conjugated. 
These nanoparticles could be controlled and moved with 
an external magnetic field allowing drug release to be 
potentially localized to a specific area. This technology 
can be used potentially in ocular diseases for intravenous 
administration of anti-VEGF agents. Thus adverse events 
and complications associated with intravitreal injection 
can be eliminated. The technology developed here can 
be used to design further nanoparticles systems which 
can examine the application of different antibodies or 
different conjugation techniques. 
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